Cost of new medications could bankrupt health care | Don Brunell

The good news is we are developing new life-saving medications every day. The bad news is they are very expensive and paying for them could bankrupt our health care system.

The good news is we are developing new life-saving medications every day. The bad news is they are very expensive and paying for them could bankrupt our health care system.

For example, Avastin, which is prescribed to treat a number of cancers, costs $100,000 a year per patient. Soliris, used to treat a rare blood and kidney disorder, costs almost $410,000 per year.

The latest medication drawing attention is Sovaldi. While highly effective in curing patients with chronic hepatitis C, it costs about $1,000 a pill or about $84,000 for a standard 12-week treatment.

Chronic hepatitis C affects 3.2 million people in the United States and about 150 million worldwide. It is a devastating virus that can be deadly if not treated effectively.  It is a blood-borne virus that causes inflammation of the liver which, if left untreated, can lead to permanent liver damage.

While it can be contracted through accidental needle sticks or long term kidney dialysis, people most at risk are IV drug users or people who use unlicensed, unclean tattoo, body piercing or acupuncture practitioners.  Most troubling, pregnant women with the disease can pass it on to their unborn babies.

Accurate statistics are difficult to come by because the virus can lie dormant for decades and experts estimate barely half of those infected have been tested.

Adding to the problem is the fact that many of those infected are unable to pay for their medical care. The Annals of Internal Medicine reports, “Our study and others have found that persons with chronic hepatitis C virus infection are frequently poor and less educated . . . .”And therein lies the dilemma.

There is no question that Sovaldi is a breakthrough drug.  It can cure patients within 12 to 24 weeks where other treatments can take up to a year. The cure rate for Sovaldi is up to 90 percent while other treatments are only about 50 percent. But its high price is driving up health care costs.Recently, Anthem Blue Cross and Blue Shield officials cited costly new hepatitis C drugs as one reason for a 12.5 percent premium increase.  And Congress, fearful of the impact on Medicaid and Medicare costs, has asked Gilead, which owns Sovaldi, to explain its pricing.We should care because we’re paying the bill.

Since Obamacare took effect in October, an estimated 7.2 million people have enrolled in its expanded Medicaid program and the Children’s Health Insurance Program, swelling the ranks to 66 million people, according to the U.S. Department of Health and Human Services. Taxpayers are responsible for subsidizing the medical care for those 66 million people.

Elected officials need to be careful here. The government can severely restrict access to high-cost drugs for Medicaid patients, increase taxes to cover the cost or try to impose price controls on drug companies.

The most politically expedient option might seem to be price controls.  But drug companies spend billions to develop these miracle drugs. The Congressional Budget Office reported in 2006 that drug companies spent on average more than $800 million to develop an innovative new drug, including the cost of failed projects and the value of forgone alternative investments.

The question is will they continue to take those risks if the government imposes price controls?

Finally, with the current focus on wellness and disease prevention, it is essential that we remind people that bad choices have bad consequences. If people understand that their bad choices lead to higher taxes and higher insurance premiums, perhaps we can put a dent in the rising cost of health care.Until that happens, we are facing some very difficult choices and there are no easy answers.


More in Business

Washington’s expensive culvert court case

Too much money is spent in court where it should go to increasing the salmon population

Straw pulp looks like a game changer

250,000 tons of straw will soon be pulped for paper products.

New Enumclaw wine bar aims for broad audience

Bordeaux Wine Bar is scheduled to be open Wednesdays through Sundays.

Streamlining regulations makes more housing affordable

There were over 21,000 people homeless in Washington State last year.

New approaches needed to fight super wildfires | Don Brunell

Last year, wildfires nationwide consumed 12,550 square miles, an area larger than Maryland.

Skilled trade jobs go unfilled in our robust economy

Known as blue collar jobs, they routinely pay $45,000 to $65,000 a year or more.

Streamlining regulations helps Americans compete

The cost of regulations is a key American competitiveness issue. It is a major reason our companies re-locate to other countries and our manufacturers and farmers have difficulties competing internationally.

Water pressure mounting in West as population spikes

What is happening in California with water allocation disputes is a harbinger of what is to come in our state as well.

Railroads implementing positive track

While the investigation continues into the deadly AMTRAK derailment near Dupont, the clock continues to tick on the implementation of Positive Track Control (PTC). The deadline is Dec. 31, 2018.

Keep the holiday spirit all year long | Don Brunell

During the holidays, our thoughts naturally turn to giving — not just giving gifts, but donating our time and money to charities, disasters and community programs.

Finding balance in occupational licensing

Recently, the Institute for Justice (Institute) determined state licensing barriers for lower-income workers and aspiring entrepreneurs not only hurts people trying to establish themselves in a profession, but annually drives consumer prices up by $203 billion.

Remember 1993

Twenty-five years ago, business took a beating in Olympia. The swing to the left in the 1992 general election was swift and potent. It drove higher costs to employers and more government regulations.